Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumorSanthosh A. Upadhyaya, Amar Gajjar, Daniel C. Moreira et al.|Neuro-Oncology|2022Cited by 29